Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
1. To assess the baseline (i.e. RA therapy initiation) characteristics in a real-world
setting across two moderate RA cohorts: a Test Group of patients newly exposed to
etanercept (Enbrel) therapy and a Control Group of patients with similar disease
characteristics newly exposed to other, non-biologic therapies.
2. To assess the change over time (from baseline to the most recent follow-up) in the
characteristics described at baseline in 2 British Society for Rheumatology Biologics
Register (BSRBR) cohorts (i.e. moderate RA patients treated with Disease modifying
anti-rheumatic drugs (DMARDs) alone versus moderate RA patients treated with Enbrel).